DMRA · Damora Therapeutics Inc. Ordinary Shares
View on chartInsiders & Stakes
| Fairmount Funds Management LLC Director | ▲ Buy | Option Exercise | 2,904,000 Shares held | 2/9/2026 | View profile |
| ORBIMED ADVISORS LLC Director | ▼ Sell | Open Market | 1,510,375 Shares held | 8/15/2023 | View profile |
| Jennifer Jarrett Director, President and CEO | ▲ Buy | Open Market | 512,500 Shares held | 9/25/2026 | View profile |
| Hewes L. Becker Chief Medical Officer | ▲ Buy | Grant | 264,629 Shares held | 1/5/2026 | View profile |
| Sattarzadeh Sherwin Chief Operating Officer | ▲ Buy | Grant | 190,376 Shares held | 1/5/2026 | View profile |
| Bruno Julianne Chief Operating Officer | ▲ Buy | Option Exercise | 137,032 Shares held | 2/9/2026 | View profile |
| Lindmark Bertil Chief Medical Officer | ▲ Buy | Open Market | 16,604 Shares held | 3/22/2022 | View profile |
| Freve Jonathan Chief Financial Officer | ▲ Buy | Open Market | 12,000 Shares held | 12/3/2021 | View profile |
| Schambye Hans T. Chief Executive Officer | ▼ Sell | Open Market | 4,682 Shares held | 1/2/2026 | View profile |
| Winslow Garrett General Counsel | ▼ Sell | Open Market | 2,289 Shares held | 7/6/2026 | View profile |
| Firmani Lori Interim CFO | ▼ Sell | Open Market | 931 Shares held | 1/2/2026 | View profile |
Transaction History
| Jennifer Jarrett | ▲ Buy | Open Market | 12,500 | $253K | 9/25/2026 |
| Winslow Garrett | ▼ Sell | Open Market | 245 | $7K | 7/6/2026 |
| Winslow Garrett | ▲ Buy | Option Exercise | 680 | — | 7/3/2026 |
| Jennifer Jarrett | ▲ Buy | Grant | 500,000 | $0 | 3/30/2026 |
| Bruno Julianne | ▲ Buy | Option Exercise | 129,000 | $0 | 2/9/2026 |
| Fairmount Funds Management LLC | ▲ Buy | Option Exercise | 5,809,000 | $0 | 2/9/2026 |
| Fairmount Funds Management LLC | ▲ Buy | Option Exercise | 2,904,000 | $0 | 2/9/2026 |
| Sattarzadeh Sherwin | ▲ Buy | Grant | 190,376 | $0 | 1/5/2026 |
| Hewes L. Becker | ▲ Buy | Grant | 264,629 | $0 | 1/5/2026 |
| Winslow Garrett | ▲ Buy | Option Exercise | 680 | — | 1/2/2026 |
| Schambye Hans T. | ▲ Buy | Option Exercise | 1,360 | — | 1/2/2026 |
| Schambye Hans T. | ▼ Sell | Open Market | 700 | $15K | 1/2/2026 |
| Winslow Garrett | ▼ Sell | Open Market | 255 | $5K | 1/2/2026 |
| Firmani Lori | ▲ Buy | Option Exercise | 374 | — | 1/2/2026 |
| Firmani Lori | ▼ Sell | Open Market | 135 | $3K | 1/2/2026 |
| Schambye Hans T. | ▲ Buy | Option Exercise | 1,360 | — | 7/3/2025 |
| Schambye Hans T. | ▼ Sell | Open Market | 735 | $2K | 7/3/2025 |
| Winslow Garrett | ▲ Buy | Option Exercise | 680 | — | 7/3/2025 |
| Winslow Garrett | ▼ Sell | Open Market | 260 | $881 | 7/3/2025 |
| Firmani Lori | ▲ Buy | Option Exercise | 374 | — | 7/3/2025 |
| Firmani Lori | ▼ Sell | Open Market | 147 | $498 | 7/3/2025 |
| Firmani Lori | ▲ Buy | Option Exercise | 726 | — | 1/3/2025 |
| Winslow Garrett | ▲ Buy | Option Exercise | 1,320 | — | 1/3/2025 |
| Winslow Garrett | ▼ Sell | Open Market | 471 | $3K | 1/3/2025 |
| Firmani Lori | ▼ Sell | Open Market | 261 | $1K | 1/3/2025 |
| Schambye Hans T. | ▲ Buy | Option Exercise | 2,640 | — | 1/3/2025 |
| Schambye Hans T. | ▼ Sell | Open Market | 1,341 | $8K | 1/3/2025 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 38,327 | $29K | 8/15/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 248,819 | $187K | 8/15/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 535,534 | $402K | 8/15/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 26,622 | $80K | 7/31/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 29,700 | $89K | 7/31/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 153,078 | $459K | 7/31/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 7,800 | $23K | 7/25/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 4,700 | $14K | 7/25/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 26,700 | $78K | 7/25/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 9,800 | $24K | 7/13/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 52,800 | $127K | 7/13/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 132,100 | $317K | 7/13/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 660 | $1K | 4/17/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 3,551 | $7K | 4/17/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 8,878 | $17K | 4/17/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 2,091 | $4K | 4/14/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 11,245 | $21K | 4/14/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 28,110 | $52K | 4/14/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 703 | $1K | 4/13/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 3,784 | $7K | 4/13/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 9,459 | $17K | 4/13/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 119 | $215 | 4/12/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 641 | $1K | 4/12/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 1,603 | $3K | 4/12/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 703 | $1K | 4/11/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 3,784 | $7K | 4/11/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 9,459 | $17K | 4/11/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 2,584 | $5K | 4/10/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 13,899 | $25K | 4/10/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 34,745 | $62K | 4/10/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 487 | $974 | 4/6/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 2,620 | $5K | 4/6/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 6,558 | $13K | 4/6/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 4,687 | $10K | 4/5/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 25,220 | $55K | 4/5/2023 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 63,058 | $137K | 4/5/2023 |
| Lindmark Bertil | ▲ Buy | Open Market | 14,604 | $32K | 3/22/2022 |
| Schambye Hans T. | ▲ Buy | Open Market | 5,000 | $11K | 3/22/2022 |
| Winslow Garrett | ▲ Buy | Open Market | 2,000 | $5K | 12/3/2021 |
| Freve Jonathan | ▲ Buy | Open Market | 4,000 | $10K | 12/3/2021 |
| Schambye Hans T. | ▲ Buy | Open Market | 4,500 | $16K | 11/9/2021 |
| Freve Jonathan | ▲ Buy | Open Market | 3,000 | $10K | 11/8/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
DMRA Shares Rise Amid Valuation Debate
Damora Therapeutics shares have climbed recently, drawing attention to potential overvaluation relative to book value. While the stock is trading near its 52-week low, analyst targets remain significantly higher than the current price. This divergence highlights a split between short-term technical weakness and long-term fundamental expectations.
DMRA Shares Rise Amid Valuation Debate. Damora Therapeutics shares have climbed recently, drawing attention to potential overvaluation relative to book value. While the stock is trading near its 52-week low, analyst targets remain significantly higher than the current price. This divergence highlights a split between short-term technical weakness and long-term fundamental expectations.